Literature DB >> 14613485

B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts.

Lucia Cicchillitti1, Sergio A Jimenez, Arturo Sala, Biagio Saitta.   

Abstract

We investigated the role of B-Myb, a cell-cycle-regulated transcription factor, in the expression of the alpha1 (I) pro-collagen gene (COL1A1) in scleroderma fibroblasts. Scleroderma or SSc (systemic sclerosis) is a fibrotic disease characterized by excessive production of extracellular matrix components, especially type I collagen. Northern-blot analysis showed an inverse relationship between COL1A1 mRNA expression and that of B-Myb during exponential cell growth and during quiescence in human SSc fibroblasts. Overexpression of B-Myb in SSc fibroblasts was correlated with decreased COL1A1 mRNA expression. Transient transfections localized the down-regulatory effect of B-Myb to a region containing the proximal 174 bp of the COL1A1 promoter that does not contain B-Myb consensus binding sites. Gel-shift analysis, using nuclear extracts from normal and SSc fibroblasts transfected with B-Myb, showed no differences in DNA-protein complex formation when compared with the nuclear extracts from mock-transfected cells. However, we found that B-Myb decreases Sp1 (specificity protein 1) and CBF (CCAAT-binding factor) binding for their specific sites localized in the 174 bp COL1A1 proximal promoter. These results were also confirmed using B-Myb-immunodepleted nuclear extracts. Furthermore, immunoprecipitation assays using SSc nuclear extracts demonstrated a physical interaction of B-Myb with Sp1 and CBF transcription factors, and also an interaction between Sp1 and CBF. In addition, by employing full-length or deleted B-Myb cDNA construct, we found that B-Myb down-regulates the COL1A1 proximal promoter through its C-terminal domain. Thus these results suggest that B-Myb may be an important factor in the pathway(s) regulating collagen production in SSc fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14613485      PMCID: PMC1223966          DOI: 10.1042/BJ20031110

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  Regulation of B-Myb activity by cyclin D1.

Authors:  S Horstmann; S Ferrari; K H Klempnauer
Journal:  Oncogene       Date:  2000-01-13       Impact factor: 9.867

2.  Functional interaction of NF-Y and Sp1 is required for type a natriuretic peptide receptor gene transcription.

Authors:  F Liang; F Schaufele; D G Gardner
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

3.  Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I.

Authors:  J Rosenbloom; B Saitta; S Gaidarova; N Sandorfi; J C Rosenbloom; W R Abrams; A D Hamilton; S M Sebti; U Kucich; S A Jimenez
Journal:  Arthritis Rheum       Date:  2000-07

4.  The retinoblastoma family member p107 binds to B-MYB and suppresses its autoregulatory activity.

Authors:  A Sala; A De Luca; A Giordano; C Peschle
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

5.  Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB.

Authors:  M Cervellera; G Raschella; G Santilli; B Tanno; A Ventura; C Mancini; C Sevignani; B Calabretta; A Sala
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

6.  Poly(ADP-ribose) polymerase is a B-MYB coactivator.

Authors:  M N Cervellera; A Sala
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

7.  Effects of B-Myb on gene transcription: phosphorylation-dependent activity ans acetylation by p300.

Authors:  Lance R Johnson; Teresa K Johnson; Michelle Desler; Troy A Luster; Tamara Nowling; Robert E Lewis; Angie Rizzino
Journal:  J Biol Chem       Date:  2001-12-03       Impact factor: 5.157

Review 8.  Alterations in the regulation of expression of the alpha 1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma).

Authors:  S A Jimenez; B Saitta
Journal:  Springer Semin Immunopathol       Date:  1999

9.  CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts.

Authors:  B Saitta; S Gaidarova; L Cicchillitti; S A Jimenez
Journal:  Arthritis Rheum       Date:  2000-10

10.  NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2.

Authors:  Z D Zhong; K Hammani; W S Bae; Y A DeClerck
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

View more
  6 in total

Review 1.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

2.  MYBL2, a link between proliferation and differentiation in maturing colon epithelial cells.

Authors:  Michael Papetti; Leonard H Augenlicht
Journal:  J Cell Physiol       Date:  2011-03       Impact factor: 6.384

3.  Interactions of two transcriptional repressors and two transcriptional activators in modulating gibberellin signaling in aleurone cells.

Authors:  Xiaolu Zou; Dawn Neuman; Qingxi J Shen
Journal:  Plant Physiol       Date:  2008-07-11       Impact factor: 8.340

Review 4.  Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

5.  Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.

Authors:  Wenling Tu; Bo Yang; Xiangyou Leng; Xue Pei; Jinyan Xu; Mohan Liu; Qiang Dong; Dachang Tao; Yongjie Lu; Yunqiang Liu; Yuan Yang
Journal:  Cancer Sci       Date:  2019-03-25       Impact factor: 6.716

6.  Significant Biomarkers Identification Associated with Cutaneous Squamous Cell Carcinoma Progression.

Authors:  Cheng-Gang Qiu; Bin Shen; Xiao-Qi Sun
Journal:  Int J Gen Med       Date:  2022-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.